TOLVAPTAN: A NOVEL DIURETIC IN HEART FAILURE MANAGEMENT

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

AMIN HILMAN ZULKIFLI; DANNY SISKA SURIDANDA

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: THE JOURNAL OF TEHRAN UNIVERSITY HEART CENTER Year:2016 | Volume:11 | Issue:1 Page(s): 1-5

Download Full-Text

View:

327

Download:

Cites:

Information Journal Paper

Title

TOLVAPTAN: A NOVEL DIURETIC IN HEART FAILURE MANAGEMENT

Author(s)

AMIN HILMAN ZULKIFLI | DANNY SISKA SURIDANDA | Issue Writer Certificate

Keywords

HEART FAILURE

ARGININE VASOPRESSIN

TOLVAPTAN

DRUG THERAPY

Abstract

HEART FAILURE (HF) is still a major problem worldwide with high morbidity and mortality rates. The recently developed medication for HF is still incapable of reducing its morbidity and mortality, and clinical data supporting the efficacy and safety of its mainstay therapy remain insufficient.Arginine-vasopressin (AVP) plays important roles in circulatory and water homeostasis, one of which is water retention through the V2 receptor. In patients with HF, there is an increased level of AVP, contributing to such symptoms as edema, dyspnea, and congestion. TOLVAPTAN as a selective V2 receptor antagonist, in addition to the conventional therapy, has been shown to cause an increase in net fluid loss, a decrease in body weight, and a reduction in the rate of HF exacerbation. Such evidence has been provided by the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist (ACTIV) in Congestive HEART FAILURE (CHF), Efficacy of Vasopressin Antagonism in HEART FAILURE Outcome Study With TOLVAPTAN (EVEREST), Acute HEART FAILURE Volume Control Multicenter Randomized (AVCMA), and Study of Ascending Levels of TOLVAPTAN in hyponatremia 1and 2 (SALT-1 and SALT-2) trials. TOLVAPTAN can be an alternative diuretic in conjunction with other standard therapies for HF and has already been proved to be able to decrease morbidity and mortality, especially in HF patients with hyponatremia.

Cites

No record.

References

AVCMA INVESTIGATORS. VASOPRESSIN V2 RECEPTOR ANTAGONIST TOLVAPTAN IS EFFECTIVE IN HEART FAILURE PATIENTS WITH REDUCED LEFT VENTRICULAR SYSTOLIC FUNCTION AND LOW BLOOD PRESSURE

Cite

APA: Copy

AMIN, HILMAN ZULKIFLI, & DANNY, SISKA SURIDANDA. (2016). TOLVAPTAN: A NOVEL DIURETIC IN HEART FAILURE MANAGEMENT. THE JOURNAL OF TEHRAN UNIVERSITY HEART CENTER, 11(1), 1-5. SID. https://sid.ir/paper/302027/en

Vancouver: Copy

AMIN HILMAN ZULKIFLI, DANNY SISKA SURIDANDA. TOLVAPTAN: A NOVEL DIURETIC IN HEART FAILURE MANAGEMENT. THE JOURNAL OF TEHRAN UNIVERSITY HEART CENTER[Internet]. 2016;11(1):1-5. Available from: https://sid.ir/paper/302027/en

IEEE: Copy

HILMAN ZULKIFLI AMIN, and SISKA SURIDANDA DANNY, “TOLVAPTAN: A NOVEL DIURETIC IN HEART FAILURE MANAGEMENT,” THE JOURNAL OF TEHRAN UNIVERSITY HEART CENTER, vol. 11, no. 1, pp. 1–5, 2016, [Online]. Available: https://sid.ir/paper/302027/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops